A Phase 3 interventional study of stop statin and switch to an antiretroviral drug with less impact on lipid metabolism in HIV Infection, sponsored by Calmy Alexandra. Completed at 7 sites in Switzerland. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-12-12.
Sponsored by Calmy Alexandra · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in HIV Infections with a site in Switzerland — 4 open to participants now, 6 under way, 3 of them phase 3. HIV Infections · Switzerland.
Among the 81 studies in HIV Infections with a site in Switzerland, this one is the 57th largest by enrollment of the 61 interventional ones that give a count, is one of 4 that started in 2011, is one of 28 in phase 3, and was the 52nd registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →4 of the 81 studies in HIV Infections with a site in Switzerland are open now. Recruiting first, the newest first:
Gilead Sciences · Sites in Switzerland, United States, Australia and 5 more countries
Ages 18+
University of Zurich · Sites in Switzerland
Ages 18+
University of Zurich · Sites in Switzerland
Ages 18+
Centre Hospitalier Universitaire Vaudois · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 14 · Phase 3 32 · Phase 4 10
First in 1999; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 438 across the 61 interventional studies, 249 across the 17 observational. Of the 68 that completed or were terminated, 28 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 81 have an industry lead sponsor. The 10 most frequent:
Calmy Alexandra is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Calmy Alexandra has 2 studies filed under HIV Infections — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 81 studies in HIV Infections with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Dyslipidaemia, characterized by raised triglyceride and low-density lipoprotein (LDL) cholesterol and reduced high-density lipoprotein (HDL) cholesterol levels, is common in HIV-infected individuals, and has been associated with HIV infection itself and antiretroviral therapy (ART). These abnormalities are well-established markers of cardiovascular (CVD) risk in the general population. Studies have suggested an increased risk of CVD associated with ART exposure over and above that conveyed by traditional cardiovascular risk factors. In HIV population to reduce lipid parameters, the most usual clinical strategy remains to add a statin treatment.
Recent studies suggested ART switch can represent an interesting alternative to statins to reduce lipid plasma levels.
The purpose of this study is to evaluate the frequency with which the replacement of LPV/r (lopinavir/ritonavir), ATZ/r (atazanavir/ritonavir), DRV/r (darunavir/ritonavir) or EFV (efavirenz) by ETR (Etravirin) in dyslipidemic patients with suppressed viremia would obviate the necessity to administer statins.
A prospective, phase III study in which the statin treatment of dyslipidemic HIV patients on antiretroviral drugs (ARVs) will be interrupted during 4 weeks is proposed.
At week 4, patients qualifying for a lipid lowering drug (calculated LDL-C≥ 3mmol/L) will replace EFV, LPV/r, DRV/r or ATZ/r by ETR. The proportion of patients not qualifying anymore for a statin treatment at 12 weeks (i.e. after 8 weeks of ETR treatment) will be determined. Additionally, the lipid level changes will be assessed at 12 weeks. Inflammatory markers will be measured at baseline, at drug switch and at the end of the study
Study drug will be provided by the drug manufacturer (Janssen-Cilag, AG). Compliance for study drug will be done at week-4 and week-12, Returned study medication will be counted and the amount notified on the Case Report Form (CRF).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in need of lipid-lowering drug switched from boosted PI or EFV to Etravirine
Drug: stop statin and switch to an antiretroviral drug with less impact on lipid metabolism
Switch from a boosted PI or efavirenz based ART regimen to etravirine 400 mg/day once daily for patients in need of lipid lowering drugs (statin) after one month wash out of statin
Proportion of patients not qualifying anymore for statin treatment
Time frame: 12 weeks
fasting lipids changes
Time frame: 12 weeks
The record gives a start of Dec 2011, a primary completion of Jul 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Calmy Alexandra